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Abstract 
This study was to investigate antimicrobial resistance and bacterial distribution of gram negative bacilli isolated from 
intensive care unit (ICU) in the First Bethune Hospital in 2009. Disk diffusion test was used to study the 
antimicrobial resistance. The data were analyzed by WHONET 5 software according to Clinical and Laboratory 
Standards Institute (CLSI). Most of 593 gram negative bacilli isolated were isolated from sputum (39.3ˁ), urine 
(23.1ˁ) and blood (9.8ˁ). Escherichia coliˈKlebsiella.sppˈpseudomonas aeruginosaˈAcinetobacter baumannii 
were the most common strains among the isolates. The rates of extended-spectrum ȕ-lactamases (ESBLs) in 
Escherichia coli and Klebsiella.spp were 53.9ˁ and 47.9ˁ, respectively. Carbapenems, cefepime, ceftazidime 
piperacillin/tazobactam, cefoperazone/sulbactam and amikacin were showed excellent activity. Bacterial distribution 
and the change of drug resistance should be investigated in order to guide rational drug usage in the clinic and 
prevent bacterial strains from being transmitted. 
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1. Introduction 
Patients in the ICU have encountered an increasing emergence and spread of antimicrobial-resistant 
pathogens. Resistance in gram negative bacilli, including Escherichia coli, Klebsiella.spp, Acinetobacter 
baumannii and Pseudomonas aeruginosa, is of great concern, because a number of reports have 
documented mechanisms whereby these microorganisms have become resistant to all available 
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antibacterial agents used in therapy. We investigated antimicrobial resistance and bacterial distribution of 
gram negative bacilli isolated from ICU in the First Bethune Hospital in 2009. 
2. Materials And Methods 
2.1 Bacterial isolates 
Consecutive nonduplicate nosocomial isolates of gram negative bacilli were collected in the First 
Bethune Hospital in 2009. Isolates were identified at the species level using standard biochemical tests 
and microbiological methods.  
2.2 Antimicrobial susceptibility testing 
The susceptibilities of gram negative bacilli to 17 antimicrobial agents were determined by the disk 
diffusion method in accordance with the Clinical and Laboratory Standards Institute(CLSI) guidelines. 
2.3 Detection of ESBLs production 
ESBLs production was detected using the double-disk synergy (DDS) test. ESBLs presence was 
assayed using the following antibiotic disks (OXOID): cefotaxime (30 ȝg), cefotaxime/clavulanic acid 
(30/10 ȝg), ceftazidime (30 ȝg), and ceftazidime/clavulanic acid (30/10ȝg). A 5-mm increase in a zone 
diameter for either antimicrobial agent tested in combination with clavulanic acid vs its zone when tested 
alone was ESBLs production. Klebsiella pneumoniae ATCC 700603 and Escherichia coli ATCC 25922 
and ATCC 35218 strains served as quality controls.  
3. Results 
Distribution of specimen type: 593 clinical isolates of gram negative bacilli were isolated. The strains 
were cultured from sputum (233 isolates, 39.3ˁ), urine (137 isolates, 23.1ˁ), blood (58 isolates, 9.8ˁ), 
pus (50 isolates, 8.4%), secretion (32 isolates, 5.4%), bile (28 isolates, 4.7%), pleural fluid (25 isolates, 
4.2%), abdominal fluid (20 isolates, 3.4%) and bone marrow (10 isolates, 1.7%). 
Distribution of gram negative bacilli: the most common bacteria isolated were Escherichia coli (228 
isolates, 38.4%), followed by Klebsiella.spp (119 isolates, 20.1%), pseudomonas aeruginosa (97 isolates, 
16.4%), Acinetobacter baumannii (78 isolates, 13.2%), Stenotrophomonas maltophilia (22 isolates, 3.7%), 
Enterobacter.spp (20 isolates, 3.4%), Proteus.spp (15 isolates, 2.5%), Citrobacter.spp (10 isolates, 1.7%) 
and Serratia marcescens (4 isolates, 0.7%). 
The rates of ESBLs in Escherichia coli and Klebsiella.spp were 53.9ˁ(123/228) and 47.9ˁ(57/119), 
respectively. 
Resistance of pseudomonas aeruginosa, Acinetobacter baumanii, ESBLs-positive and –negative 
Klebsiella.spp and Escherichia coli isolates to antibiotics is shown in table 1. 
4. Discussion 
ICU patients are at increased risk of acquiring infections, most of which are associated with the use of 
invasive devices such as indwelling catheters, central line catheters, and mechanical ventilators[1]. 
Escherichia coli, Klebsiella.spp, Acinetobacter baumannii and Pseudomonas aeruginosa are now 
widespread nosocomial pathogens in ICU. The top three specimen types in the present study were sputum, 
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urine and blood in ICU of the First Bethune Hospital in 2009. It is emphasized that gram negative bacilli
are mainly responsible for pneumonia, urinary tract infection and septicemia in ICU of the First Bethune 
Hospital. 
The present study showed prevalence of ESBLs-production ranging from 47.9ˁ ~53.9ˁ  in 
Escherichia coli and Klebsiella.spp in ICU of the First Bethune Hospital was higher in Saudi Arabia, Iran, 
Taiwan, China and Canada[2-6]. It is associated with different geography, breakpoints, or antimicrobial 
susceptibility testing. Clinical laboratories need to have adequate equipment and expertise to provide 
detection method for ESBLs. 
The resistance rates for piperacillin, ticarcillin/clavulanic acid, cefuroxime sodium, cefotaxime, 
ceftriaxone, ciprofloxacin, levofloxacin, gatifloxacin, trimethoprim/sulfamethoxazole were very high in 
ICU of the First Bethune Hospital. The resistance rates for piperacillin/tazobactam, 
cefoperazone/sulbactam, ceftazidime and cefepime to Escherichia coli, Klebsiella.spp and Pseudomonas 
were shown a relative low. The carbapenems tested in the present study showed high activity against the 
strains of Escherichia coli and Klebsiella.spp. However, 25.8%~38.5% Acinetobacter baumannii and 
Pseudomonas aeruginosa were resistant to carbapenems. 
The resistance rates of ESBLs-producing Escherichia coli and Klebsiell.spp were much higher than 
those of non-ESBLs-producing pathogens in ICU of the First Bethune Hospital in 2009. There were 
differences for ESBLs-producing Escherichia coli and Klebsiell.spp among third generation 
cephalosporins. The resistance rates to ceftazidime were among 26.3ˁ~39.0ˁ, however, those to 
cefotaxime and ceftriaxone were among 91.2ˁ~92.7ˁ in ESBLs-producing Escherichia coli and
Klebsiell.spp. The high prevalence of ESBLs-producing isolates described in this study was probably due 
to the large amount of third-generation cephalosporins consumed by patients in ICU. Carbapenems are 
effective alternative antibiotics against ESBLs-producing bacteria. 
Acinetobacter baumannii and Pseudomonas aeruginosa infections have become increasingly common 
in ICU worldwide[7-9]. The multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa shown 
high resistance to almost all antibiotics in ICU of the First Bethune Hospital. It is expected that 
multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa is a sevious infection treatment 
problem in future in ICU of the First Bethune Hospital. 
Prevention of antibiotic resistance by education regarding potential mechanisms, intermittent 
microbiologic surveillance, and use of appropriate infection-control procedures may obviate the necessity 
of restricting antibiotic use. Under these circumstances, use of an open formulary may avoid excessive use 
of certain agents. 
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.TABLE 1  Antimicrobial resistance of gram negative bacilli (%)
Antibiotics 
Escherichia coli(228) Klebsiella.spp(119) pseudomonas 
aeruginosa(97) 
Acinetobacter
baumanii (78)
ESBLs+(123) ESBLs-(105) ESBLs+(57) ESBLs-(62)
Piperacillin 97.6 47.6 98.2 51.6 51.5 87.2 
Ticarcillin/Clavulanic acid 85.4 38.1 87.7 32.3 72.2 71.8 
Piperacillin/Tazobactam 48.8 15.2 31.5 12.9 30.9 46.2 
Cefoperazone/Sulbactam 52.8 13.3 31.5 12.9 28.9 44.9 
Cefoxitin 30.1 15.2 66.7 11.3 / / 
Cefuroxime sodium 96.7 36.2 98.2 32.3 / / 
Imipenem 0.8 0.0 1.8 0.0 25.8 38.5 
Meropenem 0.8 0.0 1.8 0.0 25.8 37.2 
Ceftazidime 39.0 13.3 26.3 12.9 41.2 64.1 
Cefotaxime 92.7 17.1 91.2 14.5 72.2 71.8 
Ceftriaxone 92.7 17.1 91.2 14.5 72.2 71.8 
Cefepime 39.0 13.3 26.3 12.9 41.2 64.1 
Amikacin 32.5 29.5 47.4 30.6 36.1 51.3 
Ciprofloxacin 77.2 47.6 57.9 35.5 51.5 51.3 
Levofloxacin 73.2 42.9 52.6 25.8 46.4 47.4 
Gatifloxacin 65.0 39.0 50.9 22.6 41.2 41.0 
Trimethoprim/Sulfamethoxaz
ole 81.3 47.6 73.7 32.3 92.8 83.3 
